You have no items in your shopping cart.
EZH2 Antibody
High-Performance Anti EZH2 Antibodies for Epigenetics, PRC2, H3K27me3 Regulation, Cancer Biology and Chromatin Research.
1. Target Overview: EZH2, PRC2 & Epigenetic Gene Silencing
EZH2, also known as KMT6A, is a histone methyltransferase and the catalytic subunit of the Polycomb Repressive Complex 2 (PRC2). As the enzymatic core of PRC2, EZH2 catalyses trimethylation of histone H3 at lysine 27, generating H3K27me3, a key chromatin mark associated with transcriptional repression.
In epigenetics research, EZH2 antibodies are essential for detecting EZH2 expression, mapping subcellular localization, evaluating PRC2 pathway activity and validating chromatin-modifying drug responses. EZH2 is widely studied in cancer biology, developmental biology, stem cell regulation and gene-silencing research.
Research Relevance in Oncology: EZH2 overexpression is associated with tumour progression, metastatic behaviour, silencing of tumour suppressor genes and poor prognosis in multiple cancer types. A validated Anti EZH2 antibody is therefore a critical tool for studying epigenetic dysregulation and therapeutic response.
2. What are EZH2 antibodies used for?
A validated EZH2 antibody supports both routine detection and advanced pathway research in epigenetics, oncology and chromatin biology. Key research applications include:
- PRC2 complex biology and chromatin regulation studies
- H3K27me3 pathway research and transcriptional repression analysis
- Cancer progression, metastasis and tumour suppressor silencing studies
- Stem cell maintenance, differentiation and developmental biology
- EZH2 inhibitor response, drug screening and therapeutic validation
- Nuclear localization, co-staining and pathway interaction studies
- Comparative epigenetics in human, mouse and extended model organisms
3. Recommended EZH2 antibodies by application
Biorbyt provides a focused portfolio of EZH2 antibodies, including polyclonal, monoclonal and recombinant antibody formats. The products below are selected for common research workflows including IHC, IF, WB, FC, ELISA and IP.
SKU | Product Name | Applications | Size | Price | Best-Fit Use |
|---|---|---|---|---|---|
FC (1ug/Test) | 50 μl | $250 | Tissue staining, nuclear localization and imaging workflows | ||
Recombinant EZH2 Rabbit Monoclonal Antibody – Reproducible WB / IHC Detection | IF, IHC, WB | 25 μl | $180 | Quantitative comparison, WB and long-term reproducibility | |
ELISA, IF, IP, WB | 50 μg | $220 | Immunoprecipitation, pathway analysis and protein interaction studies | ||
ELISA, FC, IP, WB | 100 μg | $450 | Intracellular detection, ELISA, IP and functional pathway workflows | ||
FC, IHC | 100 μl | $350 | Mouse monoclonal option for IHC, co-staining and flow cytometry panels |
4. Applications & Validation
EZH2 is primarily localized in the nucleus, making antibody specificity and low background especially important for chromatin and epigenetics workflows. A carefully validated Anti EZH2 antibody helps researchers distinguish genuine nuclear EZH2 signal from non-specific staining in complex tissue and cell models.
- Immunohistochemistry (IHC-P / IHC-Fr): Useful for evaluating EZH2 expression in tumour tissues, developmental samples and formalin-fixed or frozen sections where validated.
- Immunofluorescence (IF / ICC): Enables subcellular localization, nuclear co-staining and spatial analysis of EZH2 in cultured cells or tissue models.
- Western Blot (WB): Supports total EZH2 detection and quantitative comparison across treatment groups, knockdown models or inhibitor studies.
- Flow Cytometry (FC): Supports intracellular staining workflows for comparing EZH2 expression across defined cell populations.
- Immunoprecipitation (IP): Useful for studying EZH2-associated complexes, PRC2 pathway interactions and selected protein association workflows.
- ELISA: Selected antibodies may support assay-based detection workflows where product validation is available.
Best Practice: For chromatin and inhibitor studies, pair total EZH2 detection with downstream markers such as H3K27me3. This helps connect EZH2 protein expression with PRC2 pathway activity and epigenetic repression status.
5. EZH2 inhibitor and antibody combination strategies
EZH2 is a major target in epigenetic drug development, particularly in oncology. Combining EZH2 inhibitor treatment with antibody-based detection enables researchers to monitor target expression, assess downstream chromatin effects and validate therapeutic response in cell and tissue models.
1
Treat
Apply EZH2 inhibitor treatment
Treat cells, organoids or tissue-derived models with an EZH2-targeting inhibitor under optimized dose and time-course conditions.
2
Detect
Measure EZH2 protein expression
Use EZH2 antibodies for WB, IF or IHC to evaluate changes in protein abundance, localization or treatment-associated expression patterns.
3
Validate
Assess downstream chromatin effects
Measure pathway readouts such as H3K27me3 reduction, tumour suppressor gene reactivation, cell proliferation changes or resistance-associated markers.
Recommended Antibody Strategy: Use orb1151968 for reproducible WB / IHC workflows, orb5975 for strong IF / IHC signal, and orb626869 for IP and pathway analysis.
6. EZH2 antibodies for human, mouse and diverse model systems
EZH2 is widely studied in human and mouse systems, but it is also important in non-mammalian developmental and comparative epigenetics models. Biorbyt supports both core biomedical research and specialist model organism workflows.
Model System | Recommended Use | Example Product |
|---|---|---|
Human and mouse | Cancer biology, PRC2 research, inhibitor validation and epigenetic pathway analysis | |
Zebrafish (Danio rerio) | Developmental biology, comparative epigenetics and non-mammalian EZH2 analysis | |
Xenopus models | Embryology, development and chromatin regulation studies |
7. Why choose Biorbyt EZH2 antibodies?
- Validated EZH2 antibody options for IHC, IF, FC, WB, IP and ELISA workflows.
- Polyclonal, monoclonal and recombinant antibody formats to support different assay needs.
- Recommended products for total EZH2 detection, pathway analysis and inhibitor validation.
- Strong options for human and mouse samples in oncology, epigenetics and PRC2 research.
- Support for non-mammalian model organisms including zebrafish and Xenopus.
- Compatible with chromatin regulation, H3K27me3 pathway and tumour progression studies.
- Product range designed to support both routine detection and advanced mechanistic research.
8. Companion Bioreagents & Workflow Tools
EZH2 research often requires a complete epigenetics workflow, combining total protein detection, downstream histone modification analysis and pathway validation. Biorbyt offers companion reagents to support PRC2, chromatin and cancer research.
EZH2 Antibody Recombinant EZH2 Rabbit Monoclonal Antibody Recommended for reproducible EZH2 detection in WB, IHC and IF workflows. Pathway Analysis EZH2 Antibody for IP / WB Supports immunoprecipitation and pathway analysis in PRC2 and chromatin research. Histone Mark H3K27me3 Antibodies Useful companion reagents for measuring downstream PRC2 activity and epigenetic repression. Workflow Reagents Epigenetics Research Products Explore supporting reagents for chromatin, histone modification and gene regulation studies.
9. Scientific Bibliography & Validation Sources
- Margueron, R., & Reinberg, D. (2011). The Polycomb complex PRC2 and its mark in life. Nature, 469, 343–349. doi:10.1038/nature09784
- Simon, J. A., & Kingston, R. E. (2013). Occupying chromatin: Polycomb mechanisms for getting to genomic targets, stopping transcriptional traffic, and staying put. Molecular Cell, 49(5), 808–824. doi:10.1016/j.molcel.2013.02.013
- Kim, K. H., & Roberts, C. W. M. (2016). Targeting EZH2 in cancer. Nature Medicine, 22, 128–134. doi:10.1038/nm.4036
- Comet, I., Riising, E. M., Leblanc, B., & Helin, K. (2016). Maintaining cell identity: PRC2-mediated regulation of transcription and cancer. Nature Reviews Cancer, 16, 803–810. doi:10.1038/nrc.2016.83
- Yamagishi, M., & Uchimaru, K. (2017). Targeting EZH2 in cancer therapy. Current Opinion in Oncology, 29(5), 375–381. doi:10.1097/CCO.0000000000000390